WuXi Biologics' medical research unit eyes up to $471 million in Hong Kong IPO

China-headquartered WuXi XDC, the contract medical researching unit of WuXi Biologics (Cayman) , said on Tuesday it intends to raise up to HK$3.68 billion ($470.56 million) in one of Hong Kong’s top initial public offerings this year.